Grufity logoGrufity logo

Horizon Pharma PLC Stock Research

HZNP

109.58USD+0.11(+0.10%)Market Closed

Market Summary

USD109.58+0.11
Market Closed
0.10%

HZNP Stock Price

HZNP RSI Chart

HZNP Valuation

Market Cap

24.9B

Price/Earnings (Trailing)

47.75

Price/Sales (Trailing)

6.86

EV/EBITDA

24.53

Price/Free Cashflow

20.86

HZNP Price/Sales (Trailing)

HZNP Profitability

EBT Margin

14.52%

Return on Equity

10.28%

Return on Assets

5.72%

Free Cashflow Yield

4.79%

HZNP Fundamentals

HZNP Revenue

Revenue (TTM)

3.6B

Revenue Y/Y

-7.14%

Revenue Q/Q

1.8%

HZNP Earnings

Earnings (TTM)

521.5M

Earnings Y/Y

-30.47%

Earnings Q/Q

-11.36%

Price Action

52 Week Range

57.84117.49
(Low)(High)

Last 7 days

-0.3%

Last 30 days

0.0%

Last 90 days

-3.1%

Trailing 12 Months

6.0%

HZNP Financial Health

Current Ratio

3.85

Debt/Equity

0.51

Debt/Cashflow

0.49

HZNP Investor Care

Buy Backs (1Y)

0.06%

Diluted EPS (TTM)

2.22

Peers (Alternatives to Horizon Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
404.8B
94.9B
-5.16% -10.64%
22.56
4.26
1.25% -14.07%
296.8B
28.5B
-5.67% 20.74%
47.53
10.4
0.79% 11.88%
272.8B
59.3B
-1.75% 40.02%
17.88
4.63
21.72% 11.27%
226.4B
100.3B
-8.43% -20.95%
7.22
2.26
23.43% 42.74%
142.7B
46.2B
-7.78% -1.12%
22.55
3.09
-0.49% -9.54%
MID-CAP
4.8B
4.5B
-0.20% -5.41%
-34.17
1.08
7.56% -104.06%
3.3B
2.2M
105.10% 171.03%
-10.52
1.5K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-9.96% 17.66%
31.57
2.87
15.09% 13.64%
1.6B
602.5M
-17.77% -52.80%
-2.74
2.63
18.18% -18.59%
991.7M
478.9M
-11.35% -65.42%
-0.32
2.07
-31.50% -634.70%
792.9M
285.2M
-7.22% -37.95%
3.6
2.78
-27.21% -40.28%
768.8M
114.5M
-15.28% -37.42%
-4.56
6.72
27.90% 57.40%
541.5M
29.8M
-40.95% -47.43%
-6.23
18.2
340.05% 4.35%
400.7M
51.5M
-2.49% -0.39%
-5.64
7.78
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Horizon Pharma

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-2.0%3,6293,7013,8133,7693,226
Gross Profit-2.6%2,7092,7812,8752,8602,432
Operating Expenses-0.6%2,0912,1042,0271,9631,889
  S&GA Expenses-1.7%1,5411,5671,5301,4871,446
  R&D Expenses-13.8%438508484520432
EBITDA-3.8%1,0241,0641,223917-
EBITDA Margin-1.9%0.28*0.29*0.32*0.24*-
Earnings Before Taxes-9.7%527584756807463
EBT Margin-7.9%0.15*0.16*0.20*0.21*-
Interest Expenses15.4%10692.0084.0083.0074.00
Net Income-9.2%521574765862534
Net Income Margin-7.4%0.14*0.16*0.20*0.23*-
Free Cahsflow-9.1%1,1941,3141,3461,182-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.0%9,1159,0288,8538,7408,678
  Current Assets7.1%3,6533,4123,2032,9482,800
    Cash Equivalents10.4%2,3532,1311,8931,6431,580
  Inventory-10.9%170190204227226
  Net PPE7.2%341318302295292
  Goodwill0%1,0111,0111,0111,0671,067
  Current Liabilities10.3%949861791825887
  Long Term Debt-0.1%2,5652,5672,5692,571-
Shareholder's Equity0.8%5,0725,0344,9464,8184,672
  Retained Earnings-2.7%590606584523319
  Additional Paid-In Capital1.1%4,4744,4254,3814,3154,373
Accumulated Depreciation12.7%54.0048.0042.0036.00-
Shares Outstanding-0.6%227229230229227
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-8.2%1,2581,3701,4151,2551,035
  Share Based Compensation-2.2%182186196205219
Cashflow From Investing-10.0%-134-121-231-305-2,994
Cashflow From Financing-96.3%-347-177-91.16-1091,470
  Buy Backs-44.9%250454---

Risks for HZNP

What is the probability of a big loss on HZNP?

44.6%


Probability that Horizon Pharma stock will be more than 20% underwater in next one year

34.6%


Probability that Horizon Pharma stock will be more than 30% underwater in next one year.

12.7%


Probability that Horizon Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HZNP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Horizon Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for HZNP

Cumulative Returns on HZNP

46.0%


10-Year Cumulative Returns

32.5%


7-Year Cumulative Returns

48.9%


5-Year Cumulative Returns

55.6%


3-Year Cumulative Returns

What are the long-term rolling returns for HZNP?

FIve years rolling returns for Horizon Pharma.

Annualized Returns

Which funds bought or sold HZNP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-13
Crystalline Management Inc.
new
-
5,121,000
5,121,000
2.58%
2023-03-10
MATHER GROUP, LLC.
new
-
313,974
313,974
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
6.92
9,026,730
18,370,700
0.02%
2023-03-06
Rockefeller Capital Management L.P.
added
4,314
11,474,000
11,617,000
0.06%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
sold off
-100
-
-
-%
2023-02-28
Voya Investment Management LLC
reduced
-40.25
4,201,050
46,820,000
0.07%
2023-02-24
SRS Capital Advisors, Inc.
added
193
4,349
5,349
-%
2023-02-22
CVA Family Office, LLC
sold off
-100
-
-
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
209
41,276
49,276
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-95.1
-101,797,000
10,072,700
0.01%

1–10 of 43

Latest Funds Activity

Are funds buying HZNP calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own HZNP
No. of Funds

Horizon Pharma News

Zacks Investment Research

Here's Why Horizon Therapeutics (HZNP) is a Strong Growth Stock.

Zacks Investment Research,
16 minutes ago

Business Wire

The Motley Fool

The Motley Fool

Business Insider

Schedule 13G FIlings of Horizon Pharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.37%
21,236,103
SC 13G/A
Feb 07, 2023
blackrock inc.
6.5%
14,794,254
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 03, 2022
blackrock inc.
5.7%
13,008,024
SC 13G/A
Feb 11, 2021
renaissance technologies llc
3.08%
6,798,963
SC 13G/A
Feb 10, 2021
vanguard group inc
9.03%
19,920,258
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G
Jan 29, 2021
blackrock inc.
6.4%
14,206,978
SC 13G/A
Feb 12, 2020
renaissance technologies llc
5.39%
10,100,675
SC 13G

HZNP Fair Value

Horizon Pharma fair value in different scenarios

The table shows the Fair Value estimates for Horizon Pharma for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

69.61

-36.48%

92.81

-15.30%

183.90

67.82%

308.07

181.14%

486.84

344.28%
Current Inflation

63.31

-42.22%

83.16

-24.11%

160.90

46.83%

265.29

142.10%

415.39

279.07%
Very High Inflation

55.59

-49.27%

71.53

-34.72%

133.92

22.21%

215.97

97.09%

333.79

204.61%

Historical Horizon Pharma Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Horizon Pharma

View All Filings
Date Filed Form Type Document
Mar 14, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 01, 2023
10-K
Annual Report
Mar 01, 2023
8-K
Current Report
Feb 24, 2023
8-K
Current Report
Feb 17, 2023
DEFA14A
DEFA14A
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
SC 13G/A
Major Ownership Report
Feb 08, 2023
DEFA14A
DEFA14A

Latest Insider Trading transactions for HZNP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Thompson Elizabeth H.Z.
gifted
-
-
-2,000
evp, research & development
2023-03-02
DesJardin Michael A.
acquired
66,953
15.3141
4,372
evp, technical operations
2023-03-01
Clayton Sean M.
sold (taxes)
-775,911
110
-7,032
evp, general counsel
2023-03-01
Clayton Sean M.
acquired
-
-
14,129
evp, general counsel
2023-01-17
SHERMAN JEFFREY W
gifted
-
-
-33,795
evp and chief medical officer
2023-01-17
SHERMAN JEFFREY W
gifted
-
-
33,795
evp and chief medical officer
2023-01-17
Pasternak Andy
sold
-3,066,320
113
-27,129
evp, chief strategy officer
2023-01-13
Cox Aaron
sold
-4,090,850
113
-36,148
evp, chief financial officer
2023-01-11
SHERMAN JEFFREY W
sold
-380,921
113
-3,368
evp and chief medical officer
2023-01-10
SHERMAN JEFFREY W
sold
-380,752
113
-3,368
evp and chief medical officer

1–10 of 50

Timothy P. Walbert
1890
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

HZNP Income Statement

2022-12-31
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Net sales$ 3,629,044$ 3,226,410$ 2,200,429
Cost of goods sold920,197794,512532,695
Gross profit2,708,8472,431,8981,667,734
OPERATING EXPENSES:   
Research and development437,962345,318128,999
Acquired in-process research and development and milestones56,25086,67280,365
Selling, general and administrative1,541,0521,446,410973,227
Impairment of goodwill56,171  
Impairment of long-lived asset 12,371 
Gain on sale of assets (2,000)(4,883)
Total operating expenses2,091,4351,888,7711,177,708
Operating income617,412543,127490,026
OTHER EXPENSE, NET:   
Interest expense, net(83,707)(81,063)(59,616)
Foreign exchange loss(1,202)(1,028)(297)
Loss on debt extinguishment  (31,856)
Other (expense) income, net(5,567)1,7913,388
Total other expense, net(90,476)(80,300)(88,381)
Income before expense (benefit) for income taxes526,936462,827401,645
Expense (benefit) for income taxes5,454(71,664)11,849
Net income$ 521,482$ 534,491$ 389,796
Net income per ordinary share—basic$ 2.28$ 2.37$ 1.91
Weighted average ordinary shares outstanding—basic229,108,881225,551,410203,967,246
Net income per ordinary share—diluted$ 2.22$ 2.27$ 1.81
Weighted average ordinary shares outstanding—diluted235,239,651235,680,483215,308,768
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX   
Interest rate swap contracts designated as cash flow hedges$ 23,640  
Pension and other post-employment benefit plan remeasurements4,671$ (13,296) 
Foreign currency translation adjustments(796)(1,546)$ 1,760
Other comprehensive income (loss)27,515(14,842)1,760
Comprehensive income$ 548,997$ 519,649$ 391,556

HZNP Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:  
Cash and cash equivalents$ 2,352,833$ 1,580,317
Restricted cash4,7553,839
Accounts receivable, net676,347632,775
Inventories, net169,559225,730
Prepaid expenses and other current assets449,349357,106
Total current assets3,652,8432,799,767
Property, plant and equipment, net340,509292,298
Developed technology and other intangible assets, net2,664,7772,960,118
In-process research and development810,000880,000
Goodwill1,010,5381,066,709
Deferred tax assets, net431,814538,098
Other long-term assets204,135140,738
Total assets9,114,6168,677,728
CURRENT LIABILITIES:  
Accounts payable155,80030,125
Accrued expenses and other current liabilities457,557523,015
Accrued trade discounts and rebates319,780317,431
Long-term debt—current portion16,00016,000
Total current liabilities949,137886,571
LONG-TERM LIABILITIES:  
Long-term debt, net2,546,8372,555,233
Deferred tax liabilities, net342,017390,455
Other long-term liabilities204,451173,076
Total long-term liabilities3,093,3053,118,764
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:  
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at December 31, 2022 and December 31, 2021; 227,625,913 and 227,760,936 shares issued at December 31, 2022 and December 31, 2021, respectively; and 227,241,547 and 227,376,570 shares outstanding at December 31, 2022 and December 31, 2021, respectively2323
Treasury stock, 384,366 ordinary shares at December 31, 2022 and December 31, 2021(4,585)(4,585)
Additional paid-in capital4,474,1994,373,337
Accumulated other comprehensive income (loss)12,528(14,987)
Retained earnings590,009318,605
Total shareholders’ equity5,072,1744,672,393
Total liabilities and shareholders' equity$ 9,114,616$ 8,677,728